Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3923 | mRNA-1273 Wiki | 0.52 |
drug1469 | High-dose placebo (18-59 years) & Three dose regimen Wiki | 0.45 |
drug1889 | Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
drug1472 | High-dose placebo (60-85 years) & Two dose regimen Wiki | 0.45 |
drug1470 | High-dose placebo (18-59 years) & Two dose regimen Wiki | 0.45 |
drug1891 | Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen Wiki | 0.45 |
drug3745 | avdoralimab Wiki | 0.45 |
drug1893 | Low-dose placebo (18-59 years) & Two dose regimen Wiki | 0.45 |
drug1895 | Low-dose placebo (60-85 years) & Two dose regimen Wiki | 0.45 |
drug1466 | High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen Wiki | 0.45 |
drug12 | 0.9% (w/v) saline Wiki | 0.45 |
drug1468 | High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen Wiki | 0.45 |
drug1888 | Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen Wiki | 0.45 |
drug2812 | Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) Wiki | 0.45 |
drug1465 | High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen Wiki | 0.45 |
drug1892 | Low-dose placebo (18-59 years) & Three dose regimen Wiki | 0.45 |
drug1890 | Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen Wiki | 0.45 |
drug1894 | Low-dose placebo (60-85 years) & Three dose regimen Wiki | 0.45 |
drug1471 | High-dose placebo (60-85 years) & Three dose regimen Wiki | 0.45 |
drug1467 | High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen Wiki | 0.45 |
drug128 | AZD1222 Wiki | 0.40 |
drug394 | Bacille Calmette-Guérin (BCG) Wiki | 0.32 |
drug2490 | Placebo Wiki | 0.29 |
Name (Synonyms) | Correlation | |
---|---|---|
D011014 | Pneumonia NIH | 0.32 |
D012141 | Respiratory Tract Infections NIH | 0.22 |
D000257 | Adenoviridae Infections NIH | 0.20 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002090 | Pneumonia HPO | 0.32 |
HP:0011947 | Respiratory tract infection HPO | 0.22 |
Navigate: Correlations HPO
There are 5 clinical trials
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
Description: A binary response, whereby a participant is defined as a COVID-19 case if their first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurs ≥ 15 days post second dose of study intervention. Otherwise, a participant is not defined as a COVID-19 case.
Measure: The efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults ≥ 18 years of age Time: 1 yearDescription: Incidence of adverse events. Incidence of serious adverse events, medically attended adverse events, and adverse events of special interest.
Measure: The safety and tolerability of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age Time: a: 28 days post each dose of study Intervention. / b: from Day 1 post-treatment through Day 730.Description: Incidence of local and systemic solicited adverse events.
Measure: The reactogenicity of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age (Substudy only) Time: 7 days post each dose of study intervention.Description: The proportion of participants who have a post-treatment response (negative at baseline to positive post treatment with study intervention) for SARS-CoV-2 Nucleocapsid antibodies over time.
Measure: The efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of SARS-CoV-2 infection Time: 1 yearDescription: The incidence of the first case of SARS-CoV-2 RT-PCR-positive symptomatic illness for a participant occurring at or after 15 days post second dose of study intervention using criteria from the CDC.
Measure: The efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of symptomatic COVID-19 using CDC criteria Time: 1 yearDescription: The incidence of the first case of SARS-CoV-2 RT-PCR positive symptomatic illness occurring ≥ 15 days post second dose of study intervention using University of Oxford defined symptom criteria.
Measure: The efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of University of Oxford defined symptomatic COVID-19 Time: 1 yearDescription: The incidence of SARS-CoV-RT-PCR-positive severe or critical symptomatic illness occurring 15 days or more post second dose of study intervention.
Measure: The efficacy of 2 IM doses of AZD12222 compared to placebo for the prevention of severe or critical symptomatic COVID-19. Time: 1 yearDescription: The incidence of COVID-19-related Emergency Department visits occurring ≥ 15 days post second dose of study intervention
Measure: The efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19-related Emergency Department visits Time: 1 yearDescription: Post-treatment GMTs and GMFRs in SARS-CoV-2 S, RBD antibodies (MSD serology assay); The proportion of participants who have a post-treatment seroresponse (≥ 4-fold rise in titers) to the S, RBD antigens of AZD1222 (MSD serology assay)
Measure: Antibody responses to AZD1222 S antigen following 2 IM doses of AZD1222 or placebo (Substudy and Illness Visits only) Time: 28 days post each doseDescription: Post-treatment GMTs and GMFRs in SARS-CoV-2 neutralizing antibodies (wild-type assay or pseudo-neutralization assay); Proportion of participants who have a post-treatment seroresponse (≥ 4-fold rise in titers) to AZD1222 as measured by SARS-CoV-2 neutralizing antibodies (wild-type assay or pseudo-neutralization assay)
Measure: Anti-SARS-CoV-2 neutralizing antibody levels in serum following 2 IM doses of AZD1222 or placebo (Sub-study and Illness Visits only) Time: 28 days post each doseThe mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.
Description: Clinical signs indicative of severe COVID-19 as predefined for the study.
Measure: Number of Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of mRNA-1273 Time: Day 29 (second dose) up to Day 759 (2 years after second dose)Description: Clinical signs indicative of COVID-19 and SARS-CoV-2 Infection as predefined for the study.
Measure: Number of Participants with a First Occurrence of Either COVID-19 or SARS-CoV-2 Infection regardless of symptomatology or Severity Starting 14 Days after Second Dose of mRNA-1273 or Placebo Time: Day 29 (second dose) up to Day 759 (2 years after second dose)]Description: Clinical signs indicative of secondary case definition of COVID-19 as predefined for the study.
Measure: Number of Participants with a Secondary Case Definition of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo Time: Day 29 (second dose) up to Day 759 (2 years after second dose)Description: Clinical signs indicative of COVID-19 as predefined for the study.
Measure: Number of Participants with a First Occurrence of COVID-19 Starting 14 days after First Dose of mRNA-1273 or Placebo Time: Day 1 (first dose) up to Day 759 (2 years after second dose)Description: Clinical signs indicative of COVID-19 and SARS-CoV-2 infection as predefined for the study.
Measure: Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo regardless of evidence of prior SARS-CoV-2 Infection Time: Day 29 (second dose) up to Day 759 (2 years after second dose)Description: Clinical signs indicative of COVID-19 and SARS-CoV-2 infection as predefined for the study.
Measure: Number of Participants with a First Occurrence of SARS-CoV-2 Infection in the Absence of Symptoms Defining COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo Time: Day 29 (second dose) up to Day 759 (2 years after second dose)The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the safety and reactogenicity of a single dose level of mRNA-1273 vaccine administered in 2 doses 28 days apart to an adolescent population.
Description: Acceptable serum Ab threshold as predefined for the study.
Measure: Number of Participants Who have Reached the Acceptable Threshold for the Serum Ab Level at Day 57 Time: Day 57 (28 days after second dose)Description: Clinical signs indicative of SARS-CoV-2 infection as predefined for the study.
Measure: Number of Participants with a SARS-CoV-2 Infection Starting on Day 57 Time: Day 57 up to Day 394Description: Clinical signs indicative of COVID-19 as predefined for the study.
Measure: Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo Time: Day 29 (second dose) up to Day 394 (1 year after second dose)This is a phase Ⅱ, single-center, randomized, double-blind, placebo-controlled study, to evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (Sf9 cells) in the subjects from healthy adults and elderly adults aged 18 years and above (aged 18-60 and 60-85 years) with different immunization procedures (0, 21 days and 0, 14, 28 days) and doses (20μg/40μg).
Description: Geometric mean (GMT) of specific antibody against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike protein Receptor-binding domain(S-RBD) protein (ELISA)
Measure: Geometric mean (GMT) of specific antibody Time: 1 months after immunization in each study groupDescription: The incidence of adverse reaction (AR)
Measure: The incidence of adverse reaction (AR) Time: 0 to 7 days after vaccination in each study groupDescription: The incidence of adverse events (AE)
Measure: The incidence of adverse events (AE) Time: 0 to 28 days after vaccination in each study groupDescription: The incidence of severe adverse events (SAE)
Measure: The incidence of severe adverse events (SAE) Time: 0 to 28 days after vaccination in each study groupDescription: The incidence of serious adverse events
Measure: The incidence of serious adverse events Time: 6 months after vaccination in each study groupDescription: Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies (euvirus and pseudovirus-neutralizing assays)
Measure: Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies Time: 1 months after immunization in each study groupDescription: The positive conversion rate of S-RBD protein-specific antibody (ELISA) against SARS-CoV-2
Measure: The positive conversion rate of S-RBD protein-specific antibody Time: 14 days, 30 days after immunization in each study groupDescription: Geometric mean fold increase (GMI) of S-RBD protein-specific antibody (ELISA) against SARS-CoV-2
Measure: Geometric mean fold increase (GMI) of S-RBD protein-specific antibody Time: 14 days, 30 days after immunization in each study groupDescription: Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies (euvirus and pseudovirus-neutralizing assays)
Measure: Geometric mean (GMT) of anti-SARS-CoV-2-specific neutralizing antibodies Time: 14 days after immunization in each study groupDescription: The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization test)
Measure: The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody Time: 14 days, 30 days after immunization in each study groupDescription: Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies (eucivirus and pseudovirus neutralization assays)
Measure: Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibodies Time: 14 days, 30 days after immunization in each study groupDescription: The consistency analysis of the specific antibody (ELISA) and the specific neutralizing antibody (euvirus and pseudovirus neutralization assays) against SARS-CoV-2 S-RBD protein
Measure: The consistency analysis of the specific antibody and the specific neutralizing antibody Time: 1 months after immunization in each study groupDescription: The geometric mean titer (GMT) ratio of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody in each study groups
Measure: The geometric mean titer (GMT) ratio of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody Time: 1 months after immunization in each study groupDescription: The persistence (GMT,GMI,positive conversion rate) of specific antibodies against SARS-CoV-2 S-RBD protein
Measure: The persistence (GMT,GMI,positive conversion rate) of specific antibodies Time: 6 months after vaccination in each study groupDescription: Subtypes of IgG antibodies against the S-RBD protein of SARS-CoV-2 after immunization in each study group
Measure: Subtypes of immunoglobulin G (IgG) antibodies Time: 1 months after immunization in each study groupThe COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no licensed preventions available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID 19 prevention would have significant global public health impact.
Description: The primary immunogenicity endpoint is the proportion of participants who have a post treatment seroresponse (≥ 4-fold rise in titres from Day 1 baseline value) to the Spike antigens of AZD1222 (MSD serology assay) at Day 57 , and will be calculated along with its 95% CI based on the Clopper-Pearson method in each treatment groups in each cohort (C, and D) and also Subcohorts D1, and D2 separately.
Measure: Proportion of participants who have a post treatment seroresponse to the spike antigens of AZD1222 Time: Day 57Description: The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination (Day 1 to 8).
Measure: The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination Time: Day 1 to 8Description: The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination (Day 29 to 36).
Measure: The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination Time: Day 29 to 36Description: The incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs) collected from Day 1 through Day 57.
Measure: The incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs) Time: Day 1 through Day 57Description: The change from baseline for blood chemistry measures (Creatinine in U/L ,Bilirubin in mg/dL, ALP in U/L, AST in U/L, ALT in U/L, Albumin in g/dL, Potassium in mEq/L, Calcium in mg/dL Sodium mEq/L, Creatine Kinase in U/L)
Measure: Biochemistry; change from baseline for blood chemistry measures Time: Day 8, Day 29, Day 36, and Day 57Description: The change from baseline for hematology measures (Hb in g/dL, Leukocyte in /uL, Leukocyte differential count in /uL and Platelet count in /uL)
Measure: Haematology; change from baseline for hematology/hemostasis measures Time: Day 8, Day 29, Day 36, and Day 57Description: The proportion of participants who have a post treatment seroresponse (≥ 4-fold rise in titres from Day 1 baseline value) to RBD antigens of AZD1222 (MSD serology assay) at Day 57, and will be calculated along with its 95% CI based on the Clopper-Pearson method in each treatment groups in each cohort (C, and D) and also Subcohorts D1, and D2 separately.
Measure: Proportion of participants who have a post treatment Time: Day 57Description: Geometric mean titres and geometric mean fold rise [Time Frame: Day 57 ] Geometric mean titres (GMT) and geometric mean fold rise (GMFR) of immunogenicity to Spike and RBD antigen of AZD1222 (MSD serology assay) with its 95% CI will be computed at each time point in each treatment arm in each cohort (C, and D) and also in Subcohorts D1, and D2 separately.
Measure: Genometric mean titres and genometric mean fold rise Time: Day 57Description: The proportion of participants who have a post treatment seroresponse to AZD1222 as measured by SARS-CoV-2 nAbs [Time Frame: Day 57 ] The proportion of participants who have a post treatment seroresponse (≥ 4-fold rise in titres from Day 1 baseline value) to AZD1222 as measured by SARS-CoV02 nAbs (wild-type assay or pseudoneutralisation assay) at Day 57, and will be calculated along with its 95% CI based on the Clopper-Pearson method in each treatment groups in each cohort (C, and D) and also Subcohorts D1, and D2 separately.
Measure: Proportion of participants who have a post treatment seroresponse to AZD1222 as measured by SARS-CoV-2 nAbs Time: Day 57Description: The incidence of serious adverse events (SAEs) and adverse events of special interest (AESIs) collected from Day 1 through Day 365.
Measure: The incidence of serious adverse events (SAEs) and adverse events of specisl interest (AESIs) collected from Day1 through Day365 Time: Day 1 through Day 365Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports